Neobe Therapeutics, a UK-based biotechnology company developing engineered bacteria designed to improve the effectiveness of cancer treatments, has raised $6.8 million (£5 million) in seed funding. The investment will support development of its lead therapeutic program, NEO22, with the goal of advancing the candidate through preclinical research and toward an investigational new drug filing in 2028. The financing was led by ARC Ventures, with participation from Faber, Macmillan Ventures, Proven Connect, and Empirical Ventures.
Existing investor 2048 Ventures also participated, bringing Neobe’s cumulative funding to more than $10.5 million (£7.9 million).
Founded in 2021 and headquartered in Stevenage, United Kingdom, Neobe is developing programmable bacterial therapies designed to address a significant challenge in cancer treatment: the physical barriers surrounding some solid tumors.
Although immunotherapies and other cancer medicines have produced substantial advances, many patients do not respond adequately to existing treatments.
One potential reason involves the dense, fibrous tissue surrounding certain tumors, which can prevent immune cells and therapeutic drugs from effectively reaching cancer cells.
This surrounding environment, known as the tumor microenvironment, can create structural obstacles that reduce the effectiveness of treatment.
Neobe is developing a technology platform that uses genetically engineered, nonpathogenic bacterial strains to modify these barriers.
The company’s approach involves administering engineered bacteria designed to travel to tumors and release enzymes that break down components of the surrounding tissue matrix.
By modifying the extracellular matrix, Neobe aims to make tumors more accessible to immune cells and anticancer medicines.
The technology is intended to work alongside existing cancer treatments rather than replace them.
Neobe believes that improving physical access to tumors could allow established therapies to become effective in patients whose cancers currently resist treatment.
The company has been investigating its technology through collaborations with academic researchers.
In 2026, Neobe published research in Molecular Cancer Therapeutics describing experiments conducted with scientists at the University of Cyprus and Barts Cancer Institute in London.
The research evaluated engineered bacteria in a preclinical model of triple-negative breast cancer that was resistant to a combination of immunotherapy drugs.
In one experimental model, a single dose of engineered bacteria enabled complete tumor regression when the same immunotherapy treatment was administered.
Researchers also observed that subsequent exposure to the same cancer did not lead to the development of additional tumors over the observation period.
The findings suggested the possibility of a lasting anticancer immune response.
However, these results were obtained in preclinical models, and it remains uncertain whether comparable outcomes can be achieved safely in human patients.
The research provides supporting evidence for Neobe’s approach of modifying tumor structure to improve responses to existing therapies.
Its lead program, NEO22, is being developed to translate the platform into a potential clinical treatment.
The new funding will support additional preclinical studies, manufacturing and development activities, and regulatory preparation.
Neobe is targeting an investigational new drug filing in 2028, an important milestone for initiating clinical development.
The company has also appointed Dr. Laura Chow as Chief Medical Officer.
Chow brings experience in immuno-oncology and will oversee the clinical development strategy as Neobe prepares for potential first-in-human studies.
An additional tranche associated with the seed financing is expected to support the first human clinical trial.
The participation of Macmillan Ventures, the venture investment arm of Macmillan Cancer Support, also reflects interest in technologies that could improve access to effective cancer care.
Neobe intends to continue developing its bacterial engineering platform while preparing NEO22 for regulatory evaluation.
Its longer-term objective is to develop therapies that can make existing cancer treatments more effective by modifying the tumor microenvironment.
If successful in clinical studies, the approach could eventually expand treatment options for patients with solid tumors that do not respond adequately to currently available medicines.
KEY QUOTES:
“Several treatments that can cure cancer already exist, but in far too many patients they simply cannot get to where they are needed. I’m delighted to be working with investors that share our vision of making untreatable cancers curable, and excited to move our platform towards clinical trials.”
Dr. Pedro Correa de Sampaio, Co-Founder And CEO Of Neobe Therapeutics
“We are excited to back Neobe Therapeutics’ differentiated approach to overcoming the physical barriers created by dense tumour matrices. Assets derived from Neobe’s platform will improve the efficacy of cancer therapies and extend their benefits to more patients.”
Joseph Korff, Founder Of ARC Ventures
“At Macmillan Ventures, we are working alongside people who are living with cancer today, to help shape the cancer care of tomorrow. Together, we want to break down barriers – to treatment, to care and in this case, the barrier that stands between a cancer and a treatment that could cure it. We are very proud to be supporting Neobe, and to be helping create the right environment for such promising new cancer care solutions to thrive.”
Felix Litzkow, Head Of Macmillan Ventures
“2048 Ventures is proud to have supported Neobe since their pre-seed. The mission of Neobe and its founders has always resonated with us, which is to make life-saving drugs available and effective for all patients, regardless of the tumour microenvironment. We’re thrilled to continue working with Neobe and the current syndicate toward making that vision a reality.”
Dr. Julie Wolf, Partner At 2048 Ventures

